INVO Bioscience receives Nasdaq bid-price deficiency notice; restates lease accounting for 2021–2024 periods

INVO Fertility, Inc.

Nasdaq notified INVO on Sep 18, 2024, that bid price was below $1 for 34 consecutive days; 180-day cure to May 17, 2025.
If not compliant by May 17, 2025, a second 180-day period may be granted if other initial listing standards are met.
Company considering reverse stock split among options to regain compliance.
Audit committee concluded financial statements from Jun 2021–Jun 2024 should no longer be relied upon due to incorrect discount rate used for operating lease ROU assets/liabilities.
Restatement does not affect revenue, results, EPS, or net equity; no change to operations or compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.